IgG-HD37-SMPT-dgA is a deglycosylated ricin A chain (dgA)-containing immunotoxin (IT) prepared by conjugating the monoclonal murine (MoAb) anti-CD19 antibody, HD37, t o dgA using the heterobifunctional hindered disulfide linker, N-succinimidyl-oxycarbonyl-cu-methyl-a-(2-pyridyldithio) toluene (SMPT). In this report, we have used two regimens for the administration of IgG-HD37-SMPT-dgA t o patients with non-Hodgkin's lymphoma (NHL) in two concomitant phase I trials. One trial examined four intermittent bolus infusions administered at 48-hour intervals. The other studied a continuous infusion (Cl) administered over the same 8-day period. In the intermittent bolus regimen, the maximum tolerated dose (MTD) was 16 mg/m2/8 d and the dose-limiting toxicity (DLT) consisted of vascular leak syndrome (VLS), aphasia, and evidence of rhabdomyolysis encountered at 24 mg/m2/8 d. Using the Cl regimen, the MTD was defined by VLS at 19.2 mg/mz/8 d. At the MTD of both regimens, a novel toxicity, consisting of acrocyanosis with reversible superficial distal digital skin necrosis in the absence of overt evidence of systemic vasculitis, occurred in 3 patients. Of 23 evaluable patients on the bolus schedule, there was 1 persisting complete response (CR; >40 months) and
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MMUNOTOXINS (ITS) are targeted therapeutic agents
that use an antibody or antibody fragment to target either bacterial or plant toxins to neoplastic cells in an effort to increase their therapeutic index and avoid nonspecific toxicity.',2 Lymphoid neoplasms are particularly attractive targets for ITS because the expression of several markers is both lineage and tissue specific. Hence, adult lymphoid malignancies frequently express highly restricted epitopes of CD 19,' CD22:' CD25,' and CD30. 7, 8 The toxins used in previous clinical studies in patients with lymphoid malignancies have included ricin or its A chain' and the ribosome-inactivating proteins (RIPS), saporin'" or pokeweed-antiviral protein (PAP)."." Diphtheria toxin (DAB) has also been used as 1 partial response (PR). Of 9 evaluable patients on the continuous infusion regimen, there was 1 PR. Pharmacokinetic parameters for the bolus regimen at the MTD showed a mean maximum serum concentration (Cmax) Twenty-five percent of the patients on the bolus infusion regimen and 30% on the Cl regimen made antibody against mouse lg (HAMA) and/or ricin A chain antibody (HARA). We conclude that this IT can be administered safely and that both regimens achieve comparable peak serum concentrations at the MTD; these concentrations are similar to those achieved previously using other regimens with IgG-dgA ITS at their respective MTDs. Thus, toxicity is related to the serum level of the IT and does not differ with different targeting MoAbs. 0 1996 b y The American Society of Hematology.
part of a chimeric fusion toxin."." Consistent evidence of clinical activity of ITS in lymphoid neoplasms' suggests that this strategy should be pursued.
Several clinical studies that have targeted CD19 in patients with B-cell non-Hodgkin's lymphoma (NHL) have been reported." Anti-CD19-blocked ricin (bR) IT used the anti-B4 monoclonal antibody (MoAb) chemically linked to intact ricin (A + B chain).'' The reactivity of this IT with tissues lacking the B4 epitope was diminished by chemically blocking the natural ligand-binding site of the B chain.I7 Anti-B4-bR induced clinical responses when administered either as an intermittent bolus'6 or continuous infusions" and is currently undergoing phase 111 testing after maximal cytoreduction and bone marrow transplantation.
The bR IT, which uses the B chain to facilitate the efficient internalization of the ricin A chain,'9 has carbohydrate residues on both the ricin A and B chains that are recognized by liver cells."'," Indeed, hepatotoxicity is the dose-limiting toxicity of anti-B4-bR when administered on a bolus schedule." An alternative strategy used in our studies employs ITS with dgA linked via the hindered disulfide linker, SMPT, to IgG2'.23 or via disulfide exchange to its Fab' fragment of antibody.24 Although chemical manipulations, including purification and deglycosylation of A chain are required for production of these ITS," dgA-ITs prepared with the anti-CD22 MoAb, RFB4, have had notable potency in patients with NHL."," Phase I studies of IgG-RFB4-SMPT-dgA and Fab"RFB4-dgA have been completed using an intermittent bolus s~h e d u l e~~. *~ and a continuous infusion (CI) phase I study of comparable duration has also been completed using IgG-RFB4-SMPT-dgA.2h In all instances, clinical responses were observed in 20% to 40% of the patients. and the dose-limiting toxicity (DLT) consisted of vascular leak syndrome (VLS). VLS was manifested in its mildest form by urinary sodium retention with hypoalbuminemia and in its most severe form by hypotension, noncardiogenic pulmonary edema with or without transient aphasia, rhabdomyolysis, and renal failure.
A major problem associated with antibody-based therapeutic approaches is the phenotypic heterogeneity of tumor cells. Expression of a given antigen can be focal within a tumor or can change during the natural history of a tumor. Expression may also differ at different tumor sites within a patient.28 One way to overcome this problem is to use cocktails of ITS directed against different determinants that collectively are represented on the vast majority of tumor cells and on tumor progenitor cells. Indeed, preclinical studies in SCID mice with B-cell lymphoma have shown superior therapeutic effects after treatment with a mixture of the anti-CD22 and anti-CD19 ITS as compared with optimal doses of either alone." Importantly, after chemotherapy, a cocktail of the two ITS has been curative in minimal disease in mice.3o
To obtain information that would support the notion of using IgG-HD37-SMPT-dgA in a cocktail with IgG-RFB4-SMPT-dgA to treat NHL, we have conducted phase I evaluations of IgG-HD37-SMPT-dgA as a single agent administered both by intermittent bolus and C1 schedules. As reported here, both schedules perform comparably with respect to toxicity, pharmacokinetics, immunogenicity, and clinical response.
MATERIALS AND METHODS
IgG-HD37-SMF'T-dgA was administered by either intermittent bolus administration (Baylor Hospital, Dallas, TX) or by C1 (National Cancer Institute [NCI], Bethesda, MD) for an exposure period of 8 days. The studies were approved by the institutional review boards of the two institutions, and all patients signed informed consent documents that indicated the experimental nature of the proposed therapy.
Patients
To be eligible for this study, patients were previously diagnosed with NHL of low or intermediate grade (NCI working formulation) and had failed to respond to at least one conventional combination chemotherapy regimen. Objectively measurable disease was necessary, with CD19 expressed on at least 30% of the tumor cells. Previous chemotherapy was completed at least 2 weeks before entry except for maintenance corticosteroids, the dose of which could not be escalated during the study. Patients were ineligible if they had central nervous system (CNS) or pulmonary parenchymal involvement, abnormal liver or renal function, a cardiac ejection fraction less than 35%, severe infection, antimouse antibodies greater than 1 bg/mL, human immunodeficiency virus (HIV) positivity, or an urgent local complication requiring radiation therapy or surgery.
Immunophenotyping
Biopsies were obtained for immunohistochemical or immunocytochemical cytologic analysis of CD19 expression using the HD37 antibody according to standard techniques. Eligibility could also be established by demonstrating the expression of CD19 on the monoclonal tumor cell population in bone marrow or peripheral blood as assessed by flow cytometry.
IT Preparation and Administration
IgG-HD37-SMPT-dgA was prepared as previously described" using the murine HD37 MoAb3' manufactured by Abbott Biotech (Needham, MA), the SMPT crosslinker from Pierce (Rockford, IL), and dgA from Inland Laboratories (Austin, TX). 3 The IT was administered by one of the two regimens, using intermittent bolus infusion or CI. At Baylor Hospital, dose levels were 2, 4, 8, 16, and 24 m g h ' (total dose administered over 8 days). These doses were divided into four equal doses administered every other day by a 4-hour intravenous (IV) infusion. At the NCI, the IT was administered by C1 over 8 days at two dose levels (9.6 mg/mz and 19.2 mg/m'). A test dose of 0.1 mg was administered IV before the initiation of each infusion to detect the presence of preformed antibodies not detected by the human-anti-mouse Ig antibody (HAMA) test, which might cause an anaphylactic reaction. This was not considered part of the total dose administered.
Assessment of EfJicacy
Tumor areas were determined in square centimeters before treatment and during week 4 of the study by physical examination and by computed tomography scans of'the involved areas. The total tumor area was calculated by adding the products of the largest perpendicular diameters of each lesion. A complete response (CR) was defined as the disappearance of all measurable lesions for 1 month. A partial response (PR) was defined as greater than a 50% reduction in total tumor area for more than 1 month without worsening of any lesion or appearance of a new lesion. Minor responses were recorded for the C1 regimen only and were defined as a clear biologic effect with a total tumor reduction of less than 50% for more than 1 month or more than 50% for less than 1 month. Progressive disease (PD) was defined as an increase in tumor area of more than 50% or the appearance of a clearly defined new lesion.
Assessment of Safety
The patient's physical status was assessed daily during treatment and all adverse experiences recorded and graded from I to IV, using standard toxicity scales and criteria previously reported.26 Hematologic parameters were assessed daily and blood chemistries were assessed every other day during treatment. A complete assessment (physical examination, hematology, blood chemistry, and urinalysis) was performed at the end of treatment and again 3 weeks later, at the time of tumor response. VLS is characterized by hypotension, hypoalbumenemia, edema, and weight gain. These were graded as previously reported except for weight gain and edema.26 This was graded as follows: grade I, minimal pedal edema; grade 11, weight increase by greater than I O Ib; grade 111, pulmonary edema, responding to support in less than 48 hours and weight gain less than 30 lb; grade IV, weight gain greater than 30 Ib with or without pulmonary compromise requiring ventilator support or nonresponsive to support by 48 hours.
The maximum tolerated dose (MTD) was defined as the dose below which one patient experienced grade 4 toxicity or the dose at which three or fewer patients out of six experienced grade 3 toxicity.
Pharmacokinetics
Concentrations of the IT in patient sera were measured as described previou~ly,~~ except that HD37-dgA and not RFB4-dgA was used as the standard. Pharmacokinetic parameters were determined using both compartmental and noncompartmental methods for both dose regimens and curves were generated by plotting plasma concentrations of IT versus time. Both one-and two-compartment models For personal use only. on October 27, 2017. by guest www.bloodjournal.org From The percentage of the AUC extrapolated was less than 10% for all patients. Maximum plasma concentration (C,,,,,) was determined directly from the concentration-time profile. Pharmacokinetic values for the bolus infusions are the average of the values after individual infusions.
RESULTS

Patients and Demography
Twenty-three patients were treated using the bolus infusion regimen and 10 patients were treated using the C1 regimen. Patient demographics are summarized by regimen in Table 1 . The median ages were 49 and 55 years, respectively. All patients had stage I11 or IV NHL. Patients had undergone a median of five previous treatments, respectively. Only 1 patient had undergone a single treatment before entry. Two patients in the lowest dose group of the bolus infusion regimen and 1 in the lower dose group of the C1 regimen were on maintenance corticosteroids. The patients were evenly divided between low and intermediate grades of disease (1 8/ 15). There were no significant differences in demographics between patients on the two treatment schedules. Table 2 lists the maximal toxicity grades experienced by each patient according to dose level for both the C1 and bolus dosing schedules. Table 3 lists all toxicities.
Toxicity and Safety
CZ. Using the C1 schedule, and with the exception of I nonevaluable patient, dose level I (9.6 mg/m2/8 d) was well tolerated. The nonevaluable patient had extensive disease that was refractory to both chemotherapy and radiation therapy and involved both retroperitoneal and mesenteric nodes. On day 6 of the infusion, he was noted to have decreased blood pressure, increased creatinine, and abdominal distension. Radiologic studies were compatible with a toxic megacolon. Clostridium difJicile toxin was detected in the stool, which also yielded Aeromonas on culture. He succumbed to refractory hypotension despite pressors, antibiotics, and fluids. This adverse experience can be considered a toxic death on protocol, but of uncertain relationship to the IT. Toxic megacolon is a known complication of C diflici/e infection. Its presence therefore confounded the definition of DLT. It was elected to continue dose escalation after accrual of 2 additional patients at that dose level. At dose level I1 ( 19.2 mg/m'/8 d), 3 of the 6 treated patients experienced grade I11 toxicity, thus defining the MTD. The same MTD was observed using IgG-RFB4-SMPT-dgA when administered by CL'" In 2 patients, IgG-HD37-SMPT-dgA produced grade 111 VLS at the MTD.
In the third patient who, by day 8 of the infusion, had obtained dramatic tumor shrinkage with essential resolution of a greater than 12 cm3 subcutaneous suprascapular mass. a novel grade 111 toxicity was observed. In this patient. a persisting Raynaud's-like syndrome manifested by distal upper and lower digital coldness, pallor, and acrocyanosis occurred 12 days after completing the first course of the IT. Subsequent administration of the IT at dose level I1 was withheld. Evaluation of the patient at the time of initial presentation with acrocyanosis included negative studies for HAMA and HARA. an erythrocyte sedimentation rate (ESR) of 41, a white blood cell (WBC) count of 6,800 cells/pL. 64% PMNS. 0% bands, 6% lymphocytes, 14% monocytes, 15% eosinophils. no evidence of circulating immune complexes, an IgG level of 65 1, an 1gM level of 58. but an 1gA level less than I O mg/dL. Cryoglobulins were undetectable. and the results of circulating complement activation studies showed that CH50 was not depressed, with negative ANA. anti-SSA, anti-SSB, and anti-SM. The syndrome worsened over the 2 weeks after its initial presentation, with persisting cyanosis and pallor refractory to strategies including persistent warming, nifedipine, and topically applied nitrates. Angiography showed small vessel filling defects that corresponded to the areas of cyanosis. These abnormalities were consistent with either clots or small to medium-size vessel arteritis. Although there was no systemic evidence of vasculitis or compromise of renal or CNS function, an empiric trial of pulse treatment with intravenous methylprednisolone followed by prednisone was administered at the level of 60 mg/d over a period of approximately 5 weeks, but was without obvious benefit. The syndrome resolved steadily over a period of 3 to 4 months. When the patient's disease progressed 6 months into the study, he was retreated with the same IT at 9.6 mg/m2/8 d, without recurrence ofthis toxicity. The syndrome did not recur when the patient was subsequently treated at dose level I1 of IgG-RFB4-SMPT-dgA used as a single agent.
Aside from VLS and acrocyanosis, all other adverse events in the evaluable patients on the C1 regimen were grade I or I1 and were readily reversible. Although myalgias were noted in two instances in dose level 11, there were no increases in muscle enzymes or hemepositive urine to suggest rhabdomyolysis.
Intermittent bolus infusion. In the patients treated on the intermittent bolus infusion regimen, toxicities observed at the first four dose levels (2, 4, 8, and 16 mg/m') were mild or moderate (grade I or 11) and related to VLS, fever with tachycardia, or myalgia. Because only 2 patients (both in /I Transient (<30 min) speech difficulty reported by a family member on one occasion post-discharge.
not evaluable for the duration of the response.
the lowest dose group) were on maintenance corticosteroids, it was not possible to determine whether toxicities were ameliorated by such treatment. Two patients at the 24 mg/m' dose level (no. 16 and 19) experienced grade IV elevations of creatine phosphokinase (CPK). Thus, using the intermittent bolus regimen, 16 mg/m2 defines the MTD and is concordant with the conclusion that administration of IT as a C1 does not affect the therapeutic index because the MTDs for the different regimens are very similar.
Patient no. 16 developed expressive, receptive, and anomic aphasia, with abnormal focal areas on electroencephalogram (EEG) on day 4. The results of brain magnetic resonance images (MRIs) and transcranial Doppler studies were normal. The patient also experienced dyspnea on exertion, nausea, fatigue, and myalgia. Subsequent doses were withheld. Aphasia improved by the next day, but the patient had persistent dyspnea, nausea, and myalgia and the urine output began to decrease, whereas CPK showed a mild increase to 157 U/L. By day 6, aphasia continued to improve, but the CPK level had increased to 550 to 892 U/L on repeat measurements. Fractionation of CPK isoenzymes showed that 98% were derived from skeletal muscle. The CPK reached a maximum of 1,528 U/L on day 7 (grade IV), with no elevation in the CPK MB fraction, and CPK improved daily thereafter, decreasing to normal levels by day 10. Dyspnea persisted and body weight had increased by 6.0 kg. Serum sodium was 122 * / L by day 7, having decreased steadily from 140 mEqL on day 1. Urine output was still low, ie, at 420 W 2 4 hours. On day 8, the weight continued to increase, reaching a maximum increase of 10 kg on day 9 (grade 111). Hyponatremia began to resolve on days 8 and 9, as did fatigue, dyspnea, and nausea and azotemia. All toxicities had resolved by day 14.
Patient no. 18 experienced transient (48 hours) aphasia on day 6. Because any aphasia of any severity is considered a grade I11 toxicity, administration of the IT was discontinued. This patient also experienced a steady decrease in serum sodium from 140 -/ L at entry to 127 rnEiq/L on day 8.
Patient no. 19 experienced significant weight gain that exceeded 10 kg (grade 111) by day 5. The IT was discontinued after the third dose. A sharp increase was noted in CPK on day 6 (610 U/L) accompanied by moderate myalgia. By day 7, CPK had increased to 3586 U L , urine output was noted to have decreased, and serum sodium was 129 * L , having decreased steadily from 140 mEq/L at the initiation of treatment. On day 9, abnormal CPK and serum sodium began to resolve, having reached 3,773 U/L and 127 -/L, respectively, on day 8.
Patients no. 14 and 15, who were also treated at 24 mg/ m', had Raynaud's-like syndromes similar to those described in detail for the C1 regimen. Symptoms developed 1 and 2 weeks after the end of dosing, respectively. These symptoms were mild in patient no. 15 but more severe in patient no. 14. This patient first experienced tingling in the first finger of each hand accompanied by pain and blue coloring. Bleeding with necrosis of the skin followed with loss of the nail on the left index finger. Levels of cold agglutinins and complement were normal and cryoglobulins were absent. Symptoms in both patients resolved within l month.
Overall, there was no obvious correlation between toxicities and the use of maintenance corticosteroids, disease stage, or percent CD19+ tumor cells.
EfJicacy
Clinical responses are summarized in Table 4 . One patient in each regimen studied was not evaluable for efficacy. In 1 case, the patient died of a toxic megacolon (unrelated to drug) before follow-up tumor evaluation; in the other case, treatment was never initiated due to sepsis. There was 1 CR in the bolus regimen group and 2 PRs, 1 in each regimen of the study. The CR was not noted until 2 months after the end of treatment and the patient has remained in an unmaintained complete remission for 40+ months. It is noteworthy that the CR occurred below the MTD of the regimen and was accompanied by only grade I toxicity. The duration of the PR on the C1 regimen could not be determined due to the treatment of a drug-related acrocyanosis (vide supra), but the patient was not treated for lymphoma for the 6 months after the administration of the IT. The duration of the other PR was greater than 2 months, but the patient was subsequently lost to follow-up. Twenty-one of the remaining 28 evaluable patients had either stable disease or minor responses. In contrast to patients on the low doses of the bolus regimen (2, 4, 8, and 16 mg/m2) who achieved stable disease for only a short time, at 24 mg/m2, 3 of 6 patients had stabilization of disease lasting for at least 6 months. Although we feel that this was a result of treatment, any definitive interpretation of stable disease must be tempered by the low-grade nature of the tumors and the short follow-up.
There was no obvious correlation between response and either the percentage of CD19+ tumor cells or the stage of the tumor. Table 2 summarizes the pharmacokinetic parameters as determined by a two-compartment model for each patient (C-, estimated Tin, apparent volume of distribution [Vd] at steady-state, and clearance [Cl] ). The C, , for the first dose level (9.6 mg/m2/8 d) of the C1 regimen was 348 1-208 ng/mL and 963 t 473 ng/mL for the second dose level Eighty-four courses of the bolus regimen were administered, all of which fit well to a two-compartment model. The median TI& was 18.2 hours (range, 10.0 to 80.0 hours), the Vd was 10.9 L (range, 3.1 to 34.5 L), and the Cl was 0.45 L/h (range, 0.13 to 2.3 m). There were relatively low intrapatient and interpatient variability for these parameters (CV% of 65.3%, 84.6%, and 70.7%, respectively, for the interpatient variability). Thus, the TI&, Vd, and Cl were comparable using the bolus and C1 schedules. The data fit best to a two compartment model, with a terminal TI approximately 20 hours. There was no evidence of saturable elimination at the doses used.
Pharmacokinetics
Comparing the pharmacologic behavior of the IT with variables shown previously to be related to the appearance of toxicity,26 patients who received the bolus regimen at dose levels IV and V and who experienced grade I or I1 toxicity had Cmaxs of 1,568 2 633 ng/mL as compared with 2,347 f 1,3 11 ng/mL in patients who experienced grade I11 or IV ( P > .OS). In contrast, patients on the C1 schedule who had grade I or I1 toxicity had a CmXs of 560 t 353 ng/mL, as compared with 1,196 t 477 ng/mL for those C1 patients with grade 111 toxicity ( P = .056). The mean clearance of the IT in those patients on the bolus schedule who had circulating tumor cells in the peripheral blood did not differ from that of patients without circulating tumor cells (0.58 2 0.49 v 0.72 f 0.62 Wkg, respectively), whereas in the C1 regimen, there was a trend toward increased clearance of the IT in patients with circulating peripheral tumor cells as compared with those without (0.38 t 0.18 v 0.15 f 0.03, respectively, P = .085). This finding was reflected in a trend toward a larger Vd of the IT in patients on the C1 regimen who had circulating tumor cells as compared with those without circulating tumor cells (13.5 t 6.4 v 4.9 f 0.7 L, respectively, P = .76). No difference was observed in the Vd in the bolus regimen patients in the presence or absence of circulating tumor cells (12.3 f 10 v 16.0 2 9.7 L, respectively).
HAMMHARA
As shown in Table 2 , 2 of 8 evaluable patients on the C1 regimen developed HAMA and HARA. Both patients were in the higher dose group. In the bolus dose group, only 1 of 9 evaluable patients in the first four dose levels developed Previous studies with deglycosylated ricin A chain ITS have shown clinical activity using the anti-CD22 IT, RFB4-dgA, administered either as a Fab' or IgG linked to dgA.Z5-z7 The MTDs for IgG-RFBCSMPT-dgA administered by either the bolus or C1 were similar to those observed here using IgG-HD37-SMFT-dgA. Thus, as predicted, the MTDs for dgA-based ITS are dependent on the dgA content and not on the antibody specificity. However, the MTD is clearly regimen-dependent. Hence, in another study with IgG-HD37-SMPT-dgA administered by an intensive dose regimen (3 doses over a 24-hour period), the MTD was only 8 mg/m', with significant VLS. 34 In all studies with these ITS, the DLT has been VLS, a toxicity not predicted from preclinical or toxicology studies in rhesus monkeys, mice, or guinea pigs. Although the Cl regimen did not impart a clear difference with respect to the occurrence of VLS, these patients showed no evidence of either aphasia or rhabdomyolysis. Thus, although the toxicities may be qualitatively similar, it is possible that the less marked variations in IT concentration associated with Cl result in fewer instances of some manifestations of VLS.
Recent evidence has indicated that, in the case of dgAbased ITS, VLS may result in part from direct interaction of its dgA component of the IT with endothelial cells3, and may actually reflect adventitious binding of ricin A chain to fibronectin receptors.36 These results would be consistent with the prediction that the degree to which VLS develops would be a function of both the peak serum concentration of the IT attained during the infusion and the residence time of the IT in the vascular space. It is noteworthy that, in 5 of 6 instances, patients in this trial who had grade 111 or IV toxicity had peak IT concentrations greater than 1,500 ng/ mL, in accordance with our prior observations of a direct relationship between more severe VLS and peak IT concentration greater than 1,000 n g h L Z 6 Likewise, patients in the present study who had evidence of circulating tumor cells in all cases had grade Ill or less toxicity, and the 2 patients on the bolus regimen who experienced grade IV toxicity did not have evidence of circulating tumor cells. Thus, the present results are also concordant with results of earlier studies using IgG-RFBCSMPT-dgA in that the maximal serum IT concentration and the presence of circulating tumor cells correlate directly and inversely, respectively, with severe VLS. Because the IC,, for inhibition of tumor cell growth by IgG-HD37-SMPT-dgA is approximately 10"' mom, it is clear that the range of IT concentrations achieved here exceeds that expected to kill accessible tumor cells.
Differences in the results of the current trial from those observed in prior studies with dgA-based ITS include the occurrence of acrocyanosis, the etiology of which is unclear. Although the angiographic appearance of this event is consistent either with thrombosis, embolus, or vasculitis, there was little evidence of concomitant inflammatory indices to support ongoing vasculitis, and no antigen-antibody complexes were detected. No other clinical evidence of thrombotic or embolic phenomena was evident. These results lead to the speculation that this toxicity could reflect a direct interaction of the IT with distal limb vasculature and/or microaggregation and deposition of normal or neoplastic B cells in the extremities. In this regard, we have noted that the HD37 MoAb has a tendency to form dimers and trimers, whereas RFB4 does not (Ghetie M, Vitetta ES, unpublished results). Alternatively, after interaction with the IT, material released from neoplastic or normal B cells could undergo temperature-dependent deposition in the distal vasculature.
In that regard, it is noteworthy that the patient on the C1 regimen who experienced this toxicity also achieved dramatic resolution of a symptomatic suprascapular mass before occurrence of the acrocyanosis. Whatever the explanation, this toxicity appears to be related to the use of the HD37 MoAb.
An additional distinction between the results observed here and those observed using IgG-RFBCSMPT-dgA is apparent in the pharmacologic features of the IgG-HD37-SMPT-dgA in comparison to the IgG-RFB4-SMPT-dgA. 26 The TI& of IgG-HD37-SMPT-dgA in different patients were very similar and suggested a relatively long residence time of greater than 18 hours in the circulation. In contrast, our prior study with IgG-RFBCSMPT-dgA showed great interpatient variability in the T 1 / 2~ ranging from 2.6 to 23 hours.26 In the present study, there was a good linear correlation between C,,, and dose, suggesting a linear relation between AUC and dose, without evidence of saturation. In contrast, IgG-RFB4-SMPT-dgAZ6 showed considerable variation in AUC and C, , with administered dose. Although it is certainly possible that these differences are related to the use of a different patient population, it is also possible that the two ITS have clearance mechanisms relating either to differing efficiencies of egress from the circulation or cellular uptake. This difference would reside in the specificity and not the isotypes of the MoAbs since both are of the IgGl isotype.
In comparing our results with those of Grossbard et a1,I6 who used the anti-CD19-bR IT administered by bolus regimen daily for 5 days, peak serum concentrations of approximately 2.5 nmom (approximately 730 ng/mL) were reported at MTD. These levels are comparable or slightly lower than those achieved with our bolus MTD. In the study of anti-CD19-bR IT, hepatotoxicity was dose-limiting, without overt evidence of severe VLS, although 24 of 25 patients had some degree of hypoalbuminemia. One prolonged CR and 2 PRs were observed in 25 evaluable patients in the bR IT trials as compared with the same number of responses in 23 evaluable patients treated in this trial. When used as a 7-day the MTD of the bR IT was similar; peak concentrations of the bR IT at MTD were approximately 1.5 nmom (approximately 220 ng/mL), again comparable to our experience with C1 of IgG-HD37-SMPT-dgA. The DLT of the bR IT was hepatotoxicity, but this schedule resulted in some VLS. Two CRs and 3 PRs were observed in 34 patients treated by Grossbard et as compared with 1 PR in 9 evalauble patients treated in this trial. Thus, the two anti-CD19 ITS are extremely similar with respect to both the concentrations that can be achieved at MTD and to phase I efficacy in patients with relapsed and refractory NHL. Whether this will also be the case in the setting of minimal disease remains to be determined. However, in both cases, the efficacy of these anti-CD19 ITS was less than that observed using IgG-RFB4-dgA,25.26 in accord with a poorer IC50 and less impressive antitumor activity of IgG-HD37-dgA in SCIDDaudi mice. 29 We are currently conducting a trial to determine the safety of a 50/50 mixture of IgG-HD37-SMPT-dgA and IgG-RFB4-SMPT-dgA in patients For personal use only. on October 27, 2017. by guest www.bloodjournal.org From with advanced disease and then hope to treat patients with minimal disease.
